Literature DB >> 15717277

Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.

Frithjofna Abbink1, Anne M Buisman, Gerda Doornbos, Jan Woldman, Tjeerd G Kimman, Marina A E Conyn-van Spaendonck.   

Abstract

BACKGROUND: Dutch people born between 1925 and 1945 were ineligible for vaccination with the inactivated poliovirus vaccine (IPV) introduced in 1957 and may have escaped natural infection because of reduced poliovirus circulation. We examined whether people with low or undetectable antibody levels are susceptible to infection and whether memory immunity provides protection against virus excretion.
METHODS: A total of 429 elderly participants were challenged with monovalent oral poliovirus vaccine (type 1 or 3) and followed for 8 weeks. Immune responses and virus excretion were compared for 4 groups, defined on the basis of seronegativity for poliovirus type 1 or 3, natural immunity, and IPV-induced immunity.
RESULTS: On the basis of the rapidity of the antibody response and the absence of immunoglobulin M, we saw clear evidence of memory immune responses in 33% of the participants without detectable antibodies against poliovirus type 1 and in 5% of the participants without detectable antibodies against poliovirus type 3. Fecal virus-excretion patterns were not significantly different for seronegative participants, regardless of whether they showed evidence of memory immunity.
CONCLUSIONS: Rapid antibody responses after challenge with oral polio vaccine provide evidence for poliovirus-specific memory immunity in seronegative elderly people. However, in contrast to preexisting immunity, memory immunity does not protect against virus excretion. These results have important implications for the poliomyelitis-eradication initiative, in particular for future immunization policies after eradication has been achieved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717277     DOI: 10.1086/427810

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Authors:  Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Feasibility of quantitative environmental surveillance in poliovirus eradication strategies.

Authors:  W J Lodder; A M Buisman; S A Rutjes; J C Heijne; P F Teunis; A M de Roda Husman
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

3.  Successes and shortcomings of polio eradication: a transmission modeling analysis.

Authors:  Bryan T Mayer; Joseph N S Eisenberg; Christopher J Henry; M Gabriela M Gomes; Edward L Ionides; James S Koopman
Journal:  Am J Epidemiol       Date:  2013-04-16       Impact factor: 4.897

4.  Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China.

Authors:  HaiBo Wang; Hui Cui; ZhenGrong Ding; Pian Ba; ShuangLi Zhu; Ning Wen; LiXin Hao; Jing Ning; Jie Zhang; De Yang; WenBo Xu; Yong Zhang; ChunXiang Fan; WenZhou Yu; XiaoFeng Liang; HuiMing Luo
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

5.  Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Authors:  Cynthia J Snider; Khalequ Zaman; Concepcion F Estivariz; Mohammad Yunus; William C Weldon; Kathleen A Wannemuehler; M Steven Oberste; Mark A Pallansch; Steven Gf Wassilak; Tajul Islam A Bari; Abhijeet Anand
Journal:  Lancet       Date:  2019-05-16       Impact factor: 79.321

6.  Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey.

Authors:  Gabriel Trueba; Vishali Jeyaseelan; Lazaro Lopez; Bernardo A Mainou; Yiting Zhang; Alvaro Whittembury; Alfredo Jose Olmedo Valarezo; Gonzalo Baquero; Rosa Romero de Aguinaga; Lucia Jeannete Zurita Salinas; Maria Gabriela Santacruz Mancheno; Diana Elizabeth Medina Chacho; Emmanuelle Quentin; Ana Elena Chevez; Gloria Rey-Benito; Ondrej Mach
Journal:  Lancet Reg Health Am       Date:  2022-07

Review 7.  Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus.

Authors:  Jorge Quarleri
Journal:  Geroscience       Date:  2022-10-19       Impact factor: 7.581

8.  Poor immunity status against poliomyelitis in medical students: a semi-anonymous study.

Authors:  Manuel Külshammer; Ute Winke; Monika Frank; Ursula Skali-Lami; Henrike Steudel; Gert Schilling; Jan Felix Drexler; Anna Maria Eis-Hübinger; Bertfried Matz
Journal:  Med Microbiol Immunol       Date:  2012-06-13       Impact factor: 3.402

9.  Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.

Authors:  Maren Eggers; Elena Terletskaia-Ladwig; Holger F Rabenau; Hans W Doerr; Sabine Diedrich; Gisela Enders; Martin Enders
Journal:  BMC Infect Dis       Date:  2010-12-09       Impact factor: 3.090

10.  One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.

Authors:  Ali Faisal Saleem; Ondrej Mach; Mohammad Tahir Yousafzai; Zaubina Kazi; Attaullah Baig; Muhammad Sajid; Vishali Jeyaseelan; Roland W Sutter; Anita K M Zaidi
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.